LLY · 10-Q · 2026Q3 · Full report

Incretin Revenue Concentration

ELI LILLY & Co · 2026-10-29 · Importance 68 · Surprise 24

Mounjaro, Zepbound, and Foundayo together generated 66% of Lilly's total revenue for the nine months ended September 30, 2026. The three medicines therefore represented more than two-thirds of revenue during that period. Lilly said cardiometabolic health products are expected to remain a significant and growing portion of its business, revenue, and prospects.

Key facts

• Mounjaro, Zepbound, and Foundayo accounted for 66% of Lilly's total revenue for the nine months ended September 30, 2026. source
• Lilly expects cardiometabolic health products to continue representing a significant and growing portion of its business, revenue, and prospects. source